Filed: 5/14/2026ACC: 0001193125-26-224136
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 14 equity positions with a total reported market value of $915.44M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
14
Positions
$915.44M
Total AUM (reported)
35.69M
Total Shares
Allocation by class
COMMON STOCK$796.32M87.0%
COMMON SHARES$102.08M11.2%
ORDINARY SHARES$17.04M1.9%
Portfolio Concentration
Top 3$519.61M56.8%
4–10$363.78M39.7%
11–25$32.06M3.5%
Top 3 weight
56.8%
Top 10 weight
96.5%
Voting Authority Distribution
Total shares with voting rights: 35.69M
Sole
Full voting authority
35.69M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole14
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings14
Rows:
Arcellx, Inc.
SOLEShares2.35M
TypeSH
Market value$269.44M
29.43%
Sole
2.35M
Shared
0.00
None
0.00
Veradermics, Inc.
SOLEShares2.40M
TypeSH
Market value$151.68M
16.57%
Sole
2.40M
Shared
0.00
None
0.00
Zenas BioPharma, Inc
SOLEShares5.04M
TypeSH
Market value$98.49M
10.76%
Sole
5.04M
Shared
0.00
None
0.00
CRISPR Therapeutics AG
SOLEShares2.04M
TypeSH
Market value$96.98M
10.59%
Sole
2.04M
Shared
0.00
None
0.00
Design Therapeutics, Inc.
SOLEShares6.53M
TypeSH
Market value$69.44M
7.59%
Sole
6.53M
Shared
0.00
None
0.00
ORIC Pharmaceuticals, Inc.
SOLEShares4.51M
TypeSH
Market value$58.48M
6.39%
Sole
4.51M
Shared
0.00
None
0.00
Alumis Inc.
SOLEShares1.96M
TypeSH
Market value$43.18M
4.72%
Sole
1.96M
Shared
0.00
None
0.00
Mineralys Therapeutics Inc.
SOLEShares1.56M
TypeSH
Market value$42.37M
4.63%
Sole
1.56M
Shared
0.00
None
0.00
ARS Pharmaceuticals, Inc.
SOLEShares4.01M
TypeSH
Market value$32.22M
3.52%
Sole
4.01M
Shared
0.00
None
0.00
Oruka Therapeutics, Inc
SOLEShares430.33K
TypeSH
Market value$21.11M
2.31%
Sole
430.33K
Shared
0.00
None
0.00
Oculis Holding AG
SOLEShares641.02K
TypeSH
Market value$17.04M
1.86%
Sole
641.02K
Shared
0.00
None
0.00
Nkarta, Inc.
SOLEShares3.33M
TypeSH
Market value$7.03M
0.77%
Sole
3.33M
Shared
0.00
None
0.00
enGene Holdings Inc.
SOLEShares747.75K
TypeSH
Market value$5.09M
0.56%
Sole
747.75K
Shared
0.00
None
0.00
Ultragenyx Pharmaceutical Inc.
SOLEShares137.75K
TypeSH
Market value$2.89M
0.32%
Sole
137.75K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Arcellx, Inc.SOLE | Common Stock | 2.35M | SH | $269.44M 29.43% | 2.35M | 0.00 | 0.00 |
Veradermics, Inc.SOLE | Common Stock | 2.40M | SH | $151.68M 16.57% | 2.40M | 0.00 | 0.00 |
Zenas BioPharma, IncSOLE | Common Stock | 5.04M | SH | $98.49M 10.76% | 5.04M | 0.00 | 0.00 |
CRISPR Therapeutics AGSOLE | Common Shares | 2.04M | SH | $96.98M 10.59% | 2.04M | 0.00 | 0.00 |
Design Therapeutics, Inc.SOLE | Common Stock | 6.53M | SH | $69.44M 7.59% | 6.53M | 0.00 | 0.00 |
ORIC Pharmaceuticals, Inc.SOLE | Common Stock | 4.51M | SH | $58.48M 6.39% | 4.51M | 0.00 | 0.00 |
Alumis Inc.SOLE | Common Stock | 1.96M | SH | $43.18M 4.72% | 1.96M | 0.00 | 0.00 |
Mineralys Therapeutics Inc.SOLE | Common Stock | 1.56M | SH | $42.37M 4.63% | 1.56M | 0.00 | 0.00 |
ARS Pharmaceuticals, Inc.SOLE | Common Stock | 4.01M | SH | $32.22M 3.52% | 4.01M | 0.00 | 0.00 |
Oruka Therapeutics, IncSOLE | Common Stock | 430.33K | SH | $21.11M 2.31% | 430.33K | 0.00 | 0.00 |
Oculis Holding AGSOLE | Ordinary Shares | 641.02K | SH | $17.04M 1.86% | 641.02K | 0.00 | 0.00 |
Nkarta, Inc.SOLE | Common Stock | 3.33M | SH | $7.03M 0.77% | 3.33M | 0.00 | 0.00 |
enGene Holdings Inc.SOLE | Common Shares | 747.75K | SH | $5.09M 0.56% | 747.75K | 0.00 | 0.00 |
Ultragenyx Pharmaceutical Inc.SOLE | Common Stock | 137.75K | SH | $2.89M 0.32% | 137.75K | 0.00 | 0.00 |